Novonesis (Novozymes) B (0Q4U)
LSE
445.55
-8.50 (-1.87%)
Closed
Aug 21, 2026
Day's Range
442.75450.60
52 wk Range
337.50457.50
Financial Statements - 0Q4U - Novonesis (Novozymes) B
Revenue
4.15B▲ 8.5%
Net Income
583.60M▲ 90.8%Net Margin 14.0%
EBITDA
1.44B▲ 19.6%
Free Cash Flow
750.70M▲ 13.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 4.15B | 3.83B | 321.70M | 17.55B | 14.95B | 14.01B |
| Cost of Goods | 1.91B | 2.02B | 146.96M | 7.97B | 6.32B | 6.15B |
| Gross Profit | 2.24B | 1.80B | 174.73M | 9.57B | 8.62B | 7.85B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 882.60M | 659M | 81.81M | 4.42B | 3.88B | 3.61B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 743.40M | 417.10M | 70.26M | 4.55B | 3.92B | 3.52B |
| Income Tax | 159.80M | 111.30M | 15.64M | 870M | 779M | 695M |
| Net Income | 583.60M | 305.80M | 54.62M | 3.68B | 3.14B | 2.82B |
| EPS Basic | 1.25 | 0.67 | 1.47 | 13.29 | 11.32 | 10.07 |
| EPS Diluted | 1.25 | 0.67 | 1.46 | 13.19 | 11.23 | 10.02 |
| Basic Shares Outstanding | 465.92M | 457.62M | 36.97M | 276.64M | 277.91M | 280.42M |
| Diluted Shares Outstanding | 465.92M | 457.62M | 36.97M | 276.64M | 277.91M | 280.42M |
| Ebit | 811.70M | 493.50M | 81.81M | 4.65B | 4.02B | 3.58B |
| Ebitda | 1.44B | 1.20B | 92.16M | 5.78B | 5.15B | 4.80B |
| Net Income Continuous Operations | 583.60M | 305.80M | 54.62M | 3.68B | 3.14B | 2.82B |
| Minority Interests | 0 | 0 | -2M | -10M | 1M | -1M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
